MBX (MBX Biosciences) Current Accrued Expense: $14.06 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MBX MBX Biosciences Inc MBX
14 GF Score
Price $67.72
! 3 Warning Signs
View Full Analysis

What is MBX Biosciences Current Accrued Expense?

MBX Biosciences MBX +1.06% 14 Current Accrued Expense is $14.06 Mil as of Jun. 2026. GuruFocus rates MBX with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

MBX Biosciences's Current Accrued Expense for the quarter that ended in Jun. 2026 was $14.06 Mil.

MBX Biosciences's quarterly Current Accrued Expense declined from Dec. 2025 ($8.03 Mil) to Mar. 2026 ($5.08 Mil) but then increased from Mar. 2026 ($5.08 Mil) to Jun. 2026 ($14.06 Mil).

MBX Biosciences's annual Current Accrued Expense increased from Dec. 2023 ($1.02 Mil) to Dec. 2024 ($3.22 Mil) and increased from Dec. 2024 ($3.22 Mil) to Dec. 2025 ($8.03 Mil).

MBX Biosciences Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for MBX Biosciences's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MBX Biosciences Current Accrued Expense Chart

MBX Biosciences Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
1.19 1.02 3.22 8.03

MBX Biosciences Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.71 5.36 8.03 5.08 14.06
MBX
14GF Score
MBX Biosciences Inc MBX
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MBX Biosciences Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $14.06 Mil mean?
MBX Biosciences (MBX) has a Current Accrued Expense of $14.06 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on MBX Biosciences and its competitors.
Is MBX Biosciences' Current Accrued Expense too high?
MBX Biosciences' current Current Accrued Expense is $14.06 Mil. Overall, MBX Biosciences has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does MBX Biosciences' Current Accrued Expense compare to IRON and CLDX?
MBX Biosciences' Current Accrued Expense of $14.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on MBX Biosciences and its competitors. MBX Biosciences's current Current Accrued Expense is $14.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MBX Biosciences stock overvalued right now?
MBX Biosciences (MBX) has a current Current Accrued Expense of $14.06 Mil. The current Current Accrued Expense is $14.06 Mil. MBX Biosciences' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For MBX Biosciences (MBX), the current Current Accrued Expense is $14.06 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MBX Biosciences Business Description

Address 11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
14GF Score

Get the complete analysis for MBX

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$67.72
Price